TFRC and chronic myelogenous leukemia, BCR-ABL1 positive: As observed with K562 and JURL-MK1 cells, SHIN1 treatment increased levels of GlyA and CD71 in four separate CML CD34+ patient samples, while formate supplementation reversed enhanced expression of erythroid markers (Fig. 3d).